m 2 and oxaliplatin 130 mg/m 2 on day 1, and S-1 40 mg/m 2 twice a day on days 1-14 of every 21-day cycle. This regimen seems to have promising preliminary activity. Background: Currently, the role of A20 binding and inhibitor of NF-kappaB (ABIN-1) in the development of non-small-cell lung cancer remains unknown. This retrospective study investigated expression of ABIN-1 and the association with prognosis in patients with NSCLC after lung resection. Methods: Quantitative real-time reverse transcriptase (RT)-PCR, and Western blot analyses were used to detect expression of ABIN-
1 in 30 samples of NSCLC tissue and paracarcinomatous lung tissue (PCLT), and in four samples of normal lung tissue. In addition, immunohistochemical analysis was done for 80 NSCLC specimens, and follow-up data from these patients were reviewed.
Findings: Both mRNA and protein expression of ABIN-1 were significantly raised in NSCLC tissues compared with normal lung tissues. Patients with NSCLC who had high ABIN-1 expression had shorter overall survival than patients who had low ABIN-1 expression.
Interpretation: The current data revealed that increased expression of ABIN-1 was correlated with survival in patients with NSCLC, indicating that ABIN-1 is a novel prognostic marker for NSCLC.
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The authors declared no conflicts of interest. Findings: About 80% of patients were men and 20% were women (the male-to-female ratio was 5.3:1). Clinical history was similar for both sexes, with most patients (74%) presenting with haematuria with or without altered urinary habits. WHO grading revealed 35.9% grade I, 25.4% grade II, and 38.6% of tumours as grade III. ISUP classification revealed 19.2% PNULMP, 23.6% LGPC, 39.4% HGPC, 9.6% non-papillary urothelial carcinomas (NPUC), and 7.9% as carcinoma in situ (CIS). Tumour staging depicted an overall 11.5% of tumours with stage Ta and 31.5% with stage T3-4. Among 71% invasive carcinomas, 16% were low-grade and 84% were high-grade carcinomas. Immunohistochemical staining of histological tissue sections of 73% of CIS and 84.23% of TCCs were p53 positive. 10.7% of grade I, 44.9% of grade II, and 92.1% of grade III tumours were positive for p53. There were significantly more p53-positive cases seen in grade II-III tumours than in grade I tumours (p = 0.0036). Similarly, stage T2-T4 tumours stained more frequently and stronger than stage T1 tumours (p = 0.021). No significant association between p53 status and post-operative prognosis was observed in the 3 years of followup (p = 2.131). 
Interpretation

